Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

ketamine

Drug and asset intelligence for ketamine with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
3
Stage
Development stage unavailable

Recent signals(5)

ClinicalJuly 23, 2026

Study Compares Topical Anesthesia to Propofol-Ketamine for GI Endoscopy

A clinical trial is underway to compare the efficacy and safety of a modified topical anesthesia technique against conventional intravenous sedation for upper gastrointestinal endoscopy.

ClinicalJuly 21, 2026

Ketamine Trial for Long COVID Symptoms Shows Promise for Fatigue and Brain Fog

A clinical trial is evaluating the efficacy of ketamine in treating Long COVID symptoms, particularly fatigue and cognitive issues.

ClinicalJuly 18, 2026

Phase 2 Study of Ketamine-Induced phBOLD in Healthy Volunteers

A study is underway to evaluate the effects of ketamine on brain activity using pharmacoBOLD imaging in healthy volunteers.

ClinicalJune 27, 2026

Study on Ketamine vs Fentanyl for Pain Management in Laparoscopic Cholecystectomy

A randomized double-blind study is comparing intraperitoneal ketamine and fentanyl as adjuvants to bupivacaine for postoperative pain control in laparoscopic cholecystectomy.

ClinicalJune 25, 2026

Study on Ketamine's Impact on Anaesthesia Depth Consistency in Laparoscopic Surgery

A randomized controlled study is set to evaluate the effect of subanaesthetic ketamine on anaesthesia depth consistency during laparoscopic surgery using automated propofol TIVA.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

— ketamine

July 18, 2026 · N/A

Topline Data

— ketamine

June 27, 2026 · N/A

Topline Data

— ketamine

June 25, 2026 · N/A

Indications

Infectious Disease →
Long COVID →

Therapeutic areas

Anesthesia →
Anesthesia · Ketamine →
Anesthesia · Pain Management →
Depression →
Gastroenterology →
Infectious Disease →
Ketamine →
Long COVID →
Neurology →
Neurology · Depression →
Pain Management →
Sedation →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.